B6 Phosphate
100/100
This product looks safe
- No ingredients exceed tolerable upper intake levels
- 33% of ingredients have research evidence
A
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Label Data
1 Tablet(s)
Serving Size
Other Combinations
Product Type
33%
Evidence Coverage
Supplement Facts — Evidence Check
20 mg
(1000% DV)
📊 15.4× RDA — above typical dose (UL: 100 mg)
📚 113 studies (Tier A: 3, B: 35)
Superoxide Dismutase
20 mcg
Catalase
20 mcg
Other Ingredients
Cellulose
Stearic Acid
Magnesium Stearate
Food Glaze
Label Claims — Verification
❓
All Other
All Other (98% of products)
Structure/Function (89% of products)
Nutrient (76% of products)
Target Groups
Adult (18 - 50 Years)
Product Information
📋 Directions for Use
RECOMMENDATION: One (1) tablet one (1) to three (3) times each day as a dietary supplement or as otherwise directed by a healthcare professional.
⚠️ Warnings & Precautions
KEEP OUT OF REACH OF CHILDREN
Additional Information
Store in a cool, dry area.
Sealed with an imprinted safety seal for your protection.
Rev. 1/07
Exp. Date: MAY 11
Product Details
DSLD Entry Date
2013-08-23
Product Type
Other Combinations
Form
Tablet or Pill
DSLD ID
21474
Data Updated
2026-04-11
Research Evidence
46
Research Sources
55
Avg Quality Score
23
Meta Analysis
7
Systematic Review
7
Rct
4
Clinical Trial
2
Other
1
Guideline
1
Regulatory Source
A
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
A
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
B
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
B
Radiographic and clinical outcomes of silicate-substituted calcium phosphate (SiCaP) bone grafts in spinal fusion: Systematic review and meta-analysis
B
ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium.
B
Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
B
The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Compare Similar Products
Virt-Phos 250 Neutral
Virtus Pharmaceuticals
100
Essential Minerals For Women & Men
Nature's Measure
100
Calcium & Phosphorus With Vitamin D
Sunmark
100
Av-Phos 250 Neutral
AvKARE
100
Replace SR
Endurance Products Company
100